Physician profile
Todd A Peavy
NPI 1649205956
$5,069.96
in general payments reported to CMS, 2019-2025
30 companies · $98.86 in 2025
The $98.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $528 · 2021: $2,066 · 2022: $538 · 2023: $283 · 2024: $119 · 2025: $98.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,362.88 | 2020-2021 | |
| Lilly USA, LLC | $579.82 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.73 | 2019-2025 | Jardiance |
| Pfizer INC. | $501.82 | 2019-2024 | |
| Abbvie INC. | $475.55 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $459.47 | 2019-2024 | Breztri |
| Novo Nordisk INC | $277.51 | 2020-2025 | |
| Corium, LLC | $138.90 | 2021-2024 | Azstarys |
| Dexcom, INC. | $123.59 | 2019 | |
| Supernus Pharmaceuticals, INC. | $78.38 | 2019-2022 | |
| Neos Therapeutics, LP | $72.01 | 2019 | |
| Eisai INC. | $61.24 | 2020-2022 | |
| Glaxosmithkline, LLC. | $49.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.46 | 2021 | |
| Shire North American Group INC | $35.51 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.19 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.41 | 2019 | |
| Allergan, INC. | $23.55 | 2019-2020 | |
| Abbott Laboratories | $21.25 | 2022 | |
| Amgen INC. | $20.60 | 2021 | |
| Esperion Therapeutics, INC. | $19.00 | 2021 | |
| Aytu Biopharma, INC. | $18.43 | 2019 | |
| Vifor Pharma, INC. | $18.11 | 2022 | |
| Gilead Sciences, INC. | $17.92 | 2023 | |
| Genentech USA, INC. | $17.73 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.00 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $15.89 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.22 | 2023 | Quviviq |
| Celgene Corporation | $14.13 | 2019 | |
| Adlon Therapeutics L.P. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Peavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.